Accelerating purification process development of an early phase MAb with high-throughput automation

BioProcess International

Volumn 12, Issue 3, 2014, Pages 48-52

  Chollangi, Srinivas ^a   Jaffe, Neil E ^a   Cai, Hui ^a   Bell, Amanda ^a   Patel, Krina ^a   Fischl, Mark ^a   Russell, Reb J ^a   Cheng, Kuang Chuan ^a   Wang, Michelle Jue ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ARTICLE; BUFFER EXCHANGE CHROMATOGRAPHY; CHO CELL; DEVELOPMENTAL STAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL PERMEATION CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HOST CELL; ION EXCHANGE CHROMATOGRAPHY; NONHUMAN; PROCESS DEVELOPMENT; PURIFICATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ULTRAVIOLET SPECTROSCOPY;

EID: 84898854115     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (30)

1. Gottschalk U. The Renaissance of Protein Purification. BioPharm Int. 19, 2006: S8-S9.
2. Reichert JM, et al. Monoclonal Antibody Successes in the Clinic. Nat. Biotechnol. 23, 2005: 1073-1078. (Pubitemid 41486385)
3. DiMasi JA, Hansen RW, Grabowski HG. The Price of Innovation: New Estimates of Drug Development Costs. J. Health Econ. 22, 2003: 151-185. (Pubitemid 36279392)
4. Datar RV, Cartwright T, Rosen CG. Process Economics of Animal Cell and Bacterial Fermentations: A Case Study Analysis of Tissue Plasminogen Activator. Biotechnol. 11, 1993: 349-357. (Pubitemid 23081286)
5. Sadana A, Beelaram AM. Efficiency and Economics of Bioseparation: Some Case Studies. Bioseparation 4, 1994: 221-235. (Pubitemid 2117636)
6. Clemento A. New and Integrated Approaches to Successful Accelerated Drug Development. Drug Info. J. 33, 1999: 699-710. (Pubitemid 29399760)
7. Werner RG. Economic Aspects of Commercial Manufacture of Biopharmaceuticals. J. Biotechnol. 113, 2004: 171-182. (Pubitemid 39237078)
8. Sommerfeld S, Strube J. Challenges in Biotechnology Production: Generic Processes and Process Optimization for Monoclonal Antibodies. Chem. Eng. Processing 44, 2005: 231-236.
9. Li F, et al. Current Therapeutic Antibody Production and Process Optimization. BioProcessing J. 4, 2005: 1-8.
10. Kelley B, Blank G, Lee A. Downstream Processing of Monoclonal Antibodies: Current Practices and Future Opportunities. Process Scale Purification of Antibodies. Gottshalk U, Ed. John Wiley and Sons: Hoboken, NJ, 2009; 1-23.
11. Vunnum S, Vedantham G, Hubbard B. Protein A-Based Affinity Chromatography. Process Scale Purification of Antibodies. Gottshalk U, Ed. John Wiley and Sons: Hoboken, NJ, 2009; 79-102.
12. Zhou J, Dehghani H. Development of Viral Clearance Strategies for Large-Scale Monoclonal Antibody Production. Advances in Large Scale Biomanufacturing and Scale-Up Production. Langer ES, Ed. ASM Press/BioPlan Associates Inc.: Rockville, MD, 2007; 1-28.
13. Shi L, et al. Real Time Quantitative PCR As a Method to Evaluate Xenotropic Murine Leukemia Virus Removal During Pharmaceutical Protein Purification. Biotechnol. Bioeng. 87, 2004: 884-896. (Pubitemid 39265085)
14. Bray J, Brattle K. Monoclonal Antibody Production: Minimizing Virus Safety Issues, Volume 1. Plenum Publishers: New York, NY, 2004.
15. CPMP/BWP/269/95. Note for Guidance on Virus Validation Studies. EMA: London, UK, 2001.
16. Coffman JL, Kramarczyk JF, Kelley BD. High-Throughput Screening of Chromatographic Separations: I, Method Development and Column Modeling. Biotechnol. Bioeng. 100, 2008: 605-618. (Pubitemid 351913988)
17. Kelley BD, et al. High-Throughput Screening of Chromatographic Separations: IV, Ion-Exchange. Biotechnol. Bioeng. 100, 2008: 950-963.
18. Kramarczyk JF, Kelley BD, Coffman JL. High-Throughput Screening of Chromatographic Separations: II, Hydrophobic Interaction. Biotechnol. Bioeng. 100, 2008: 707-720. (Pubitemid 351913998)
19. Gallop MA, et al. Applications of Combinatorial Technologies to Drug Discovery: 1, Background and Peptide Combinatorial Libraries. J. Med. Chem. 37, 1994: 1233-1251. (Pubitemid 24179463)
20. Gordon EM, et al. Applications of Combinatorial Technologies to Drug Discovery: 2, Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions. J. Med. Chem. 37, 1994: 1385-1401. (Pubitemid 24174073)
21. Van Hijfte L, Marciniak G, Froloff N. Combinatorial Chemistry, Automation and Molecular Diversity: New Trends in the Pharmaceutical Industry. J. Chromatogr. B Biomed. Sci. Appl. 725, 1999: 3-15. (Pubitemid 30173217)
22. Janzen WP. High Throughput Screening As a Discovery Tool in the Pharmaceutical Industry. Lab. Robotics Automat. 8, 1996: 261-265. (Pubitemid 126652686)
23. Kenney BA, et al. The Application of High-Throughput Screening to Novel Lead Discovery. Progr. Drug Res. 51, 1998: 246-269.
24. Barrett RW, et al. Selective Enrichment and Characterization of High Affinity Ligands from Collections of Random Peptides on Filamentous Phage. Analyt. Biochem. 204, 1992: 357-364.
25. Oldenburg KR, et al. Peptide Ligands for a Sugar-Binding Protein Isolated from a Random Peptide Library. Proc. Natl. Acad. Sci. USA 89, 1992: 5393-5397.
26. Scott JK, Smith GP. Searching for Peptide Ligands with an Epitope Library. Science 249, 1990: 386-390.
27. Kramarczyk JF. High-Throughput Screening of Chromatographic Resins and Excipients for Optimizing Selectivity. Tufts University: Medford, MA, 2003.
28. Lacki KM. High-Throughput Process Development of Chromatography Steps: Advantages and Limitations of Different Formats Used. Biotechnol. J. 7, 2012: 1192-1202.
29. Chatre S, Titchener-Hooker NJ. Microscale Methods for High-Throughput Chromatography Development in the Pharmaceutical Industry. J. Chem. Technol. Biotechnol. 84, 2009: 927-940.
30. Chatre S, Bracewell DG, Titchener-Hooker NJ. A Microscale Approach for Predicting the Performance of Chromatography Columns Used to Recover Therapeutic Polyclonal Antibodies. J. Chromatogr. A 1216, 2009: 7806-7815.